Sumitomo Mitsui Trust Holdings Divests Takeda Voting Power

TL;DR

**Sumitomo Mitsui Trust Holdings now has zero sole voting power in Takeda as of Dec 31, 2023.**

AI Summary

Sumitomo Mitsui Trust Holdings, Inc. filed an Amendment No. 3 to its SC 13G/A for Takeda Pharmaceutical Company Limited, indicating a change in their beneficial ownership as of December 31, 2023. The filing shows that Sumitomo Mitsui Trust Holdings, Inc. now holds 0 shares with sole voting power in Takeda Pharmaceutical Company Limited. This matters to investors because it signals a complete divestment of voting power by a significant institutional holder, which could impact perceptions of institutional confidence in Takeda.

Why It Matters

This filing indicates a major institutional investor, Sumitomo Mitsui Trust Holdings, Inc., no longer holds any sole voting power in Takeda Pharmaceutical Company Limited, which could be interpreted as a loss of confidence or a strategic portfolio reallocation.

Risk Assessment

Risk Level: medium — The complete divestment of sole voting power by a large institutional investor could signal potential concerns or a lack of conviction in the company's future performance.

Analyst Insight

Investors should investigate the reasons behind Sumitomo Mitsui Trust Holdings, Inc.'s complete divestment of sole voting power in Takeda Pharmaceutical Company Limited and consider if this signals broader concerns about the company's outlook.

Key Numbers

• 0 — Sole Voting Power (Number of shares with sole voting power held by Sumitomo Mitsui Trust Holdings, Inc. in Takeda Pharmaceutical Company Limited as of December 31, 2023.)

Key Players & Entities

• Sumitomo Mitsui Trust Holdings, Inc. (company) — the reporting person who filed the SC 13G/A
• Takeda Pharmaceutical Company Limited (company) — the issuer of the securities
• December 31, 2023 (date) — the date of the event requiring the filing
• Japan (company) — place of organization for Sumitomo Mitsui Trust Holdings, Inc.

Forward-Looking Statements

• Other institutional investors may re-evaluate their positions in Takeda Pharmaceutical Company Limited following this divestment. (Takeda Pharmaceutical Company Limited) — medium confidence, target: Q2 2024

FAQ

Filing Documents

• tak131246sc13ga3.htm (SC 13G/A) — 35KB
• 0001214659-24-001876.txt ( ) — 37KB

(a). Name of Issuer

Item 1(a). Name of Issuer: Takeda Pharmaceutical Company Limited

(b). Address of Issuer’s Principal

Item 1(b). Address of Issuer’s Principal Executive Offices: 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan

(a). Name of Person Filing

Item 2(a). Name of Person Filing: Sumitomo Mitsui Trust Holdings, Inc.

(b). Address of Principal Business Office

Item 2(b). Address of Principal Business Office or, if None, Residence: 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan

(c). Citizenship

Item 2(c). Citizenship: Japan

(d). Title of Class of Securities

Item 2(d). Title of Class of Securities: Common Stock

(e). CUSIP Number

Item 2(e). CUSIP Number: 874060205

If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a

Item 3. If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Parent Holding Company Page 3 of 6

Ownership

Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1. (a) Amount beneficially owned: 87,400,834 (b) Percent of class: 5.5% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 79,074,334 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 87,400,834

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. See Exhibit A.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group. Not applicable.

Certifications

Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Page 4 of 6 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 5, 2024 Sumitomo Mitsui Trust Holdings, Inc. (Company) /s/ Hideaki Takamiya (Signature) Hideaki Takamiya / Senior Manager of Risk Management Dept (Name/Title) Page 5 of 6 Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, portions of the securities being reported on by Sumitomo Mitsui Trust Holdings, Inc. as a parent holding company are owned, or may be deemed to be beneficially owned, by its subsidiaries: each of (a) Sumitomo Mitsui Trust Asset Management Co., Ltd. and (b) Nikko Asset Management Co., Ltd. is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E) and as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J). Page 6 of 6

View Full Filing

View this SC 13G/A filing on SEC EDGAR